Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm |
Domain |
PF12799 Leucine Rich repeats (2 copies) PF13516 Leucine Rich repeat |
Function |
Probable regulator of the NF-kappa-B and type I interferon signaling pathways. May also regulate the type II interferon signaling pathway. Plays a role in homeostatic control of innate immunity and in antiviral defense mechanisms. |
Biological Process |
GO:0001818 negative regulation of cytokine production GO:0001959 regulation of cytokine-mediated signaling pathway GO:0001960 negative regulation of cytokine-mediated signaling pathway GO:0001961 positive regulation of cytokine-mediated signaling pathway GO:0002683 negative regulation of immune system process GO:0009615 response to virus GO:0031348 negative regulation of defense response GO:0031349 positive regulation of defense response GO:0032088 negative regulation of NF-kappaB transcription factor activity GO:0032479 regulation of type I interferon production GO:0032480 negative regulation of type I interferon production GO:0032606 type I interferon production GO:0034340 response to type I interferon GO:0034341 response to interferon-gamma GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045341 MHC class I biosynthetic process GO:0045343 regulation of MHC class I biosynthetic process GO:0045345 positive regulation of MHC class I biosynthetic process GO:0045824 negative regulation of innate immune response GO:0050777 negative regulation of immune response GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051607 defense response to virus GO:0060330 regulation of response to interferon-gamma GO:0060332 positive regulation of response to interferon-gamma GO:0060333 interferon-gamma-mediated signaling pathway GO:0060334 regulation of interferon-gamma-mediated signaling pathway GO:0060335 positive regulation of interferon-gamma-mediated signaling pathway GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060339 negative regulation of type I interferon-mediated signaling pathway GO:0060340 positive regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0060760 positive regulation of response to cytokine stimulus GO:0060761 negative regulation of response to cytokine stimulus GO:0071346 cellular response to interferon-gamma GO:0071357 cellular response to type I interferon GO:0098542 defense response to other organism |
Molecular Function |
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding GO:0001046 core promoter sequence-specific DNA binding GO:0001047 core promoter binding |
Cellular Component | - |
KEGG | - |
Reactome |
R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways |
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between NLRC5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between NLRC5 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of NLRC5 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of NLRC5 in various data sets.
|
Points in the above scatter plot represent the mutation difference of NLRC5 in various data sets.
|
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLRC5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLRC5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLRC5. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLRC5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of NLRC5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between NLRC5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | NLRC5 |
Name | NLR family, CARD domain containing 5 |
Aliases | NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ...... |
Chromosomal Location | 16q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting NLRC5 collected from DrugBank database. |
There is no record. |